RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptive Biotechnologies Stock

Adaptive Biotechnologies ROCE 2025

Adaptive Biotechnologies ROCE

-0.65

Ticker

ADPT

ISIN

US00650F1093

WKN

A2PLR5

In 2025, Adaptive Biotechnologies's return on capital employed (ROCE) was -0.65, a 52.76% increase from the -0.43 ROCE in the previous year.

Adaptive Biotechnologies Aktienanalyse

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry. Adaptive Biotechnologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Adaptive Biotechnologies's Return on Capital Employed (ROCE)

Adaptive Biotechnologies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Adaptive Biotechnologies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Adaptive Biotechnologies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Adaptive Biotechnologies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Adaptive Biotechnologies stock

What is the ROCE (Return on Capital Employed) of Adaptive Biotechnologies this year?

The ROCE of Adaptive Biotechnologies is -0.65 undefined this year.

How has the ROCE (Return on Capital Employed) of Adaptive Biotechnologies developed compared to the previous year?

The ROCE of Adaptive Biotechnologies has increased by 52.76% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Adaptive Biotechnologies?

A high Return on Capital Employed (ROCE) indicates that Adaptive Biotechnologies has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Adaptive Biotechnologies?

A low ROCE (Return on Capital Employed) can indicate that Adaptive Biotechnologies has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Adaptive Biotechnologies impact the company?

An increase in the ROCE of Adaptive Biotechnologies can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Adaptive Biotechnologies affect the company?

A decrease in ROCE of Adaptive Biotechnologies can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Adaptive Biotechnologies?

Some factors that can affect Adaptive Biotechnologies's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Adaptive Biotechnologies so important for investors?

The ROCE of Adaptive Biotechnologies is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Adaptive Biotechnologies take to improve the ROCE?

To improve the ROCE, Adaptive Biotechnologies can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Adaptive Biotechnologies pay?

Over the past 12 months, Adaptive Biotechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptive Biotechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptive Biotechnologies?

The current dividend yield of Adaptive Biotechnologies is .

When does Adaptive Biotechnologies pay dividends?

Adaptive Biotechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptive Biotechnologies?

Adaptive Biotechnologies paid dividends every year for the past 0 years.

What is the dividend of Adaptive Biotechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptive Biotechnologies located?

Adaptive Biotechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptive Biotechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptive Biotechnologies from 2/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/18/2025.

When did Adaptive Biotechnologies pay the last dividend?

The last dividend was paid out on 2/18/2025.

What was the dividend of Adaptive Biotechnologies in the year 2024?

In the year 2024, Adaptive Biotechnologies distributed 0 USD as dividends.

In which currency does Adaptive Biotechnologies pay out the dividend?

The dividends of Adaptive Biotechnologies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adaptive Biotechnologies

Our stock analysis for Adaptive Biotechnologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.